CASP9 and neoplasm: Furthermore, we have identified one of its direct and key targets—CASP9—which in turn, mediates tumor proliferation, migration, and invasion through cell apoptosis pathways, providing evidence in support of targeting miR-224/CASP9 in TNBC therapy.